Cite
HARVARD Citation
Dorr, M. et al. (n.d.). Bezlotoxumab (BEZ) for Prevention of Clostridium difficile Infection (CDI) Recurrence (rCDI): Distinguishing Relapse from Reinfection with Whole Genome Sequencing (WGS). Open forum infectious diseases. pp. S388-S389. [Online].